Skip to main content
Year archive

Strategic Partners A/S — 2020 filings

All 129 regulatory filings released by Strategic Partners A/S (STRAP) in 2020, sourced directly from the official regulator.

129 Filings
2020 Period
2020 filings (129)
Filing Released Lang
Orphazyme provides regulatory update on arimoclomol for NPC
Regulatory Filings
2020-12-27 English
Legal Proceedings Report 2020
Legal Proceedings Report
2020-12-27 English
Kim Stratton, CEO, resigns from Orphazyme
Board/Management Information
2020-12-10 English
Board/Management Information 2020
Board/Management Information
2020-12-10 English
Orphazyme submits European Marketing Authorisation Application for arimoclomol for treatment of Niemann-Pick disease Type C
Regulatory Filings
2020-11-09 English
Regulatory Filings 2020
Regulatory Filings
2020-11-09 English
Share Issue/Capital Change 2020
Share Issue/Capital Change
2020-11-03 English
End of stabilization period
Regulatory Filings
2020-11-03 English
Share Issue/Capital Change 2020
Share Issue/Capital Change
2020-10-27 English
Stabilization measures taken
Regulatory Filings
2020-10-27 English
Stabilization measures taken
Capital/Financing Update
2020-10-27 English
Earnings Release 2020
Earnings Release FY 2020
2020-10-23 English
Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020
Earnings Release FY 2020
2020-10-23 English
Stabilization measures taken
Regulatory Filings
2020-10-16 English
Stabilization measures taken
Regulatory Filings
2020-10-16 English
Capital/Financing Update 2020
Capital/Financing Update
2020-10-16 English
Major shareholder announcement
Major Shareholding Notification
2020-10-09 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-10-09 English
Stabilization measures taken
Capital/Financing Update
2020-10-08 English
Stabilization measures taken
Regulatory Filings
2020-10-08 English
Regulatory Filings 2020
Regulatory Filings
2020-10-08 English
Major shareholder announcement
Major Shareholding Notification
2020-10-05 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-10-05 English
Major shareholder announcement
Major Shareholding Notification
2020-10-05 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-10-05 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-10-02 English
Director's Dealing 2020
Director's Dealing
2020-10-02 English
Major shareholder announcement
Major Shareholding Notification
2020-10-01 English
Major shareholder announcement
Major Shareholding Notification
2020-10-01 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-10-01 English
Share Issue/Capital Change 2020
Share Issue/Capital Change
2020-09-30 English
Orphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering
Share Issue/Capital Change
2020-09-30 English
Stabilization period begins
Regulatory Filings
2020-09-29 English
Capital/Financing Update 2020
Capital/Financing Update
2020-09-29 English
Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Share Issue/Capital Change
2020-09-29 English
Share Issue/Capital Change 2020
Share Issue/Capital Change
2020-09-29 English
Orphazyme A/S provides update on previously announced global offering
Capital/Financing Update
2020-09-25 English
Capital/Financing Update 2020
Capital/Financing Update
2020-09-25 English
Share Issue/Capital Change 2020
Share Issue/Capital Change
2020-09-21 English
Orphazyme A/S commences a global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe
Capital/Financing Update
2020-09-21 English
Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C
Regulatory Filings
2020-09-16 English
Regulatory Filings 2020
Regulatory Filings
2020-09-16 English
Capital increase of 1,927 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2020-09-01 English
Capital increase of 1,927 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2020-09-01 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-09-01 English
Director's Dealing 2020
Director's Dealing
2020-09-01 English
Orphazyme announces Interim Report First Half 2020
Interim / Quarterly Report H1 2020
2020-08-28 English
Report Publication Announcement 2020
Report Publication Announcement H1 2020
2020-08-28 English
Capital increase of 31,250 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
Share Issue/Capital Change
2020-07-31 English
Capital increase of 31,250 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
Share Issue/Capital Change
2020-07-31 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-07-29 English
Director's Dealing 2020
Director's Dealing
2020-07-29 English
Director's Dealing 2020
Director's Dealing
2020-07-16 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-07-16 English
Director's Dealing 2020
Director's Dealing
2020-07-15 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-07-15 English
Capital increase of 3,451 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2020-07-07 English
Capital increase of 3,451 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2020-07-07 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-07-03 English
Director's Dealing 2020
Director's Dealing
2020-07-03 English
Orphazyme announces confidential submission of a draft registration statement for a potential registered public offering in the United States
Capital/Financing Update
2020-07-01 English
Capital/Financing Update 2020
Capital/Financing Update
2020-07-01 English
Orphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers
Regulatory Filings
2020-06-24 English
Earnings Release 2020
Earnings Release FY 2020
2020-06-24 English
Major shareholder announcement
Major Shareholding Notification
2020-05-29 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-05-29 English
Orphazyme initiates rolling submission of New Drug Application for arimoclomol with US FDA in Niemann-Pick disease Type C
Regulatory Filings
2020-05-29 English
Regulatory Filings 2020
Regulatory Filings
2020-05-29 English
Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis
Regulatory Filings
2020-05-22 English
Regulatory Filings 2020
Regulatory Filings
2020-05-22 English
Capital increase of 1,927 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2020-04-23 English
Capital increase of 1,927 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2020-04-23 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-04-22 English
Director's Dealing 2020
Director's Dealing
2020-04-22 English
Capital increase of 4,616 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2020-04-20 English
Capital increase of 4,616 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Share Issue/Capital Change
2020-04-20 English
Director's Dealing 2020
Director's Dealing
2020-04-17 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-04-17 English
Orphazyme publishes listing prospectus in connection with listing of shares
Share Issue/Capital Change
2020-03-16 English
Share Issue/Capital Change 2020
Share Issue/Capital Change
2020-03-16 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-03-11 English
Director's Dealing 2020
Director's Dealing
2020-03-11 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-03-10 English
Director's Dealing 2020
Director's Dealing
2020-03-10 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-03-04 English
Director's Dealing 2020
Director's Dealing
2020-03-04 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-03-03 English
Director's Dealing 2020
Director's Dealing
2020-03-03 English
Major shareholder announcement
Major Shareholding Notification
2020-03-02 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-03-02 English
Orphazyme announces Annual Report 2019
Report Publication Announcement
2020-02-28 English
Orphazyme announces Annual Report 2019
Report Publication Announcement
2020-02-28 English
Annual Report 2019
Annual Report FY 2019
2020-02-28 English
Major shareholder announcement
Major Shareholding Notification
2020-02-13 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-13 English
Major shareholder announcement
Major Shareholding Notification
2020-02-12 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-12 English
Major shareholder announcement
Major Shareholding Notification
2020-02-11 English
Major shareholder announcement
Major Shareholding Notification
2020-02-11 English
Major shareholder announcement
Major Shareholding Notification
2020-02-11 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-11 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-11 English
Major shareholder announcement
Major Shareholding Notification
2020-02-11 English
Director's Dealing 2020
Director's Dealing
2020-02-11 English
Orphazyme completes registration of share capital increases of an aggregated nominal value of DKK 7,032,937
Share Issue/Capital Change
2020-02-11 English
Orphazyme completes registration of share capital increases of an aggregated nominal value of DKK 7,032,937
Share Issue/Capital Change
2020-02-11 English
Announcement of treasury shares
Transaction in Own Shares
2020-02-07 English
Share Issue/Capital Change 2020
Share Issue/Capital Change
2020-02-07 English
Orphazyme completes offering of 7,032,937 shares in a directed issue and private placement and raises approximately DKK 745,000,000 (EUR 100 million/USD 110 million)
Share Issue/Capital Change
2020-02-07 English
Capital/Financing Update 2020
Capital/Financing Update
2020-02-07 English
Announcement of treasury shares
Transaction in Own Shares
2020-02-06 English
Transaction in Own Shares 2020
Transaction in Own Shares
2020-02-06 English
Major shareholder announcement
Major Shareholding Notification
2020-02-06 English
Major shareholder announcement
Major Shareholding Notification
2020-02-06 English
Major shareholder announcement
Major Shareholding Notification
2020-02-06 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-06 English
Director's Dealing 2020
Director's Dealing
2020-02-06 English
Orphazyme initiates directed issue and private placement of shares
Share Issue/Capital Change
2020-02-06 English
Capital/Financing Update 2020
Capital/Financing Update
2020-02-06 English
Preliminary results for 2019 and financial outlook for 2020
Earnings Release FY 2019
2020-02-04 English
Earnings Release 2019
Earnings Release FY 2019
2020-02-04 English
Capital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Share Issue/Capital Change
2020-01-31 English
Capital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Share Issue/Capital Change
2020-01-31 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing
2020-01-07 English
Director's Dealing 2020
Director's Dealing
2020-01-07 English
Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
Regulatory Filings
2020-01-06 English
Regulatory Filings 2020
Regulatory Filings
2020-01-06 English
Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
Regulatory Filings
2020-01-03 English
Legal Proceedings Report 2020
Legal Proceedings Report
2020-01-03 English